Market LIVE
Published markets; coverage varies by country
Product profile · United States

CABENUVA KIT

 ·  Patent Litigation & Settlement History ↓

IngredientCABOTEGRAVIR; RILPIVIRINE
Application typeNDA
Application212888
Product002
Dosage formSUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
Strength600MG/3ML (200MG/ML);900MG/3ML (300MG/ML)
Approval date2021-01-21
Marketing statusPrescription
Status event—
ApplicantVIIV HLTHCARE
Product source

Current GenericRadar decision

Year2031
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typePATENT
Anchor date2031-02-04
Patent anchor2031-02-04
Exclusivity anchor2026-01-21
Protection date2040-10-01
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2031. Anchor type: PATENT. Patent anchor: 2031-02-04. Exclusivity anchor: 2026-01-21. Anchor date: 2031-02-04. Patent tail: yes. Exclusivity tail: no. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
109271292026-04-28DS/DP —YNTRUE_DS
English description not available.
———
109271292026-04-28ORANGE_BOOK —YNTRUE_DS
English description not available.
———
113894472027-06-30U U-3405NNU
English description not available.
———
113894472027-06-30ORANGE_BOOK U-3405NNU
English description not available.
———
84101032031-02-04DS/DP/U U-3348YNTRUE_DS
English description not available.
———
84101032031-02-04ORANGE_BOOK U-3348YNTRUE_DS
English description not available.
———
112245972031-09-15DP/U U-3348NNDP
English description not available.
———
112245972031-09-15ORANGE_BOOK U-3348NNDP
English description not available.
———
121382642031-09-15DP/U U-3348NNDP
English description not available.
———
121382642031-09-15ORANGE_BOOK U-3348NNDP
English description not available.
———
RE501892031-11-27U U-3348NNU
English description not available.
———
RE501892031-11-27ORANGE_BOOK U-3348NNU
English description not available.
———
113894482032-04-13DP —NNDP
English description not available.
———
113894482032-04-13ORANGE_BOOK —NNDP
English description not available.
———
121788152038-07-18U U-3348NNU
English description not available.
———
121788152038-07-18ORANGE_BOOK U-3348NNU
English description not available.
———
126362852040-10-01U U-3348NNU
English description not available.
———
126362852040-10-01ORANGE_BOOK U-3348NNU
English description not available.
———
126362862040-10-01U U-3348NNU
English description not available.
———
126362862040-10-01ORANGE_BOOK U-3348NNU
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
D-1842022-01-312025-01-31English description not available.NN—
NCE
Full coverage date: —
Source
NPP2022-03-292025-03-29English description not available.NN—
NCE
Full coverage date: —
Source
NCE2021-01-212026-01-21English description not available.YY2026-01-21—Source
NCE2021-01-212026-01-21English description not available.YY2026-01-21
NCE
Full coverage date: 2026-01-21
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (14)
TypeDateRoleBasisSource
PATENT2026-04-28HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2027-06-30HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2031-02-04CANONICAL_ANCHOREnglish description not available.Source
PATENT2031-09-15FTO_TAILEnglish description not available.Source
PATENT2031-09-15FTO_TAILEnglish description not available.Source
PATENT2031-11-27FTO_TAILEnglish description not available.Source
PATENT2032-04-13FTO_TAILEnglish description not available.Source
PATENT2038-07-18FTO_TAILEnglish description not available.Source
PATENT2040-10-01FTO_TAILEnglish description not available.Source
PATENT2040-10-01FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_STATUS2031-02-04CANONICAL_DECISIONEnglish description not available.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.